KR20210142004A - 과민성 방광을 치료하기 위한 비베그론의 용도 - Google Patents

과민성 방광을 치료하기 위한 비베그론의 용도 Download PDF

Info

Publication number
KR20210142004A
KR20210142004A KR1020217033037A KR20217033037A KR20210142004A KR 20210142004 A KR20210142004 A KR 20210142004A KR 1020217033037 A KR1020217033037 A KR 1020217033037A KR 20217033037 A KR20217033037 A KR 20217033037A KR 20210142004 A KR20210142004 A KR 20210142004A
Authority
KR
South Korea
Prior art keywords
subject
vibegron
treatment
placebo
mean
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217033037A
Other languages
English (en)
Korean (ko)
Inventor
주니어 폴 엔. 머드
Original Assignee
유로반트 사이언시즈 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유로반트 사이언시즈 게엠베하 filed Critical 유로반트 사이언시즈 게엠베하
Priority to KR1020267009764A priority Critical patent/KR20260049872A/ko
Publication of KR20210142004A publication Critical patent/KR20210142004A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217033037A 2019-03-18 2020-03-18 과민성 방광을 치료하기 위한 비베그론의 용도 Ceased KR20210142004A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020267009764A KR20260049872A (ko) 2019-03-18 2020-03-18 과민성 방광을 치료하기 위한 비베그론의 용도

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962820230P 2019-03-18 2019-03-18
US62/820,230 2019-03-18
US201962830302P 2019-04-05 2019-04-05
US62/830,302 2019-04-05
US201962842435P 2019-05-02 2019-05-02
US62/842,435 2019-05-02
US201962885767P 2019-08-12 2019-08-12
US62/885,767 2019-08-12
US201962897019P 2019-09-06 2019-09-06
US62/897,019 2019-09-06
US201962904429P 2019-09-23 2019-09-23
US62/904,429 2019-09-23
PCT/IB2020/052484 WO2020188505A1 (en) 2019-03-18 2020-03-18 Use of vibegron to treat overactive bladder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020267009764A Division KR20260049872A (ko) 2019-03-18 2020-03-18 과민성 방광을 치료하기 위한 비베그론의 용도

Publications (1)

Publication Number Publication Date
KR20210142004A true KR20210142004A (ko) 2021-11-23

Family

ID=70166082

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217033037A Ceased KR20210142004A (ko) 2019-03-18 2020-03-18 과민성 방광을 치료하기 위한 비베그론의 용도
KR1020267009764A Pending KR20260049872A (ko) 2019-03-18 2020-03-18 과민성 방광을 치료하기 위한 비베그론의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020267009764A Pending KR20260049872A (ko) 2019-03-18 2020-03-18 과민성 방광을 치료하기 위한 비베그론의 용도

Country Status (14)

Country Link
US (1) US20230027066A1 (https=)
EP (1) EP3941473A1 (https=)
JP (2) JP2022524576A (https=)
KR (2) KR20210142004A (https=)
CN (2) CN121489955A (https=)
AU (2) AU2020243514A1 (https=)
BR (1) BR112021017198A2 (https=)
CA (1) CA3129024A1 (https=)
IL (1) IL285910A (https=)
MX (1) MX2021009488A (https=)
PH (1) PH12021551975A1 (https=)
SG (1) SG11202108810YA (https=)
TW (2) TW202102221A (https=)
WO (1) WO2020188505A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3634420A1 (en) 2017-06-06 2020-04-15 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
SG11202103662VA (en) 2018-12-05 2021-06-29 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
TW202245781A (zh) * 2021-02-16 2022-12-01 瑞士商優洛凡特科學公司 用維貝格龍（ｖｉｂｅｇｒｏｎ）治療心臟衰竭之方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
RS59402B1 (sr) 2013-03-15 2019-11-29 Merck Sharp & Dohme Postupak za pripremu beta 3 agonista i međuproizvoda
JP6197971B1 (ja) * 2016-04-22 2017-09-20 小野薬品工業株式会社 Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤
US20170348288A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
US10057209B2 (en) * 2016-07-28 2018-08-21 Qualcomm Incorporated Time-sequenced multi-device address assignment
JP7670461B2 (ja) * 2017-06-06 2025-04-30 ウロバント サイエンシズ ゲゼルシャフト ミット ベシュレンクター ハフトゥング 過活動膀胱の治療のためのビベグロンの投薬
EP3634420A1 (en) * 2017-06-06 2020-04-15 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
EP3583905A1 (en) * 2018-06-20 2019-12-25 Arthrex Inc Percutaneous targeting device

Also Published As

Publication number Publication date
CN113840607A (zh) 2021-12-24
SG11202108810YA (en) 2021-10-28
AU2020243514A1 (en) 2021-08-26
AU2025256180A1 (en) 2025-11-13
MX2021009488A (es) 2021-09-21
TW202506129A (zh) 2025-02-16
WO2020188505A1 (en) 2020-09-24
CN121489955A (zh) 2026-02-10
JP2022524576A (ja) 2022-05-09
EP3941473A1 (en) 2022-01-26
JP2025084777A (ja) 2025-06-03
BR112021017198A2 (pt) 2021-11-16
CA3129024A1 (en) 2020-09-24
TW202102221A (zh) 2021-01-16
PH12021551975A1 (en) 2022-07-04
IL285910A (en) 2021-10-31
KR20260049872A (ko) 2026-04-14
US20230027066A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
JP2025084777A (ja) 過活動膀胱を処置するためのビベグロンの使用
JP2011511782A (ja) 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
US20230218624A1 (en) Dosing of vibegron for treatment of overactive bladder
JP2025032143A (ja) 良性前立腺肥大症の男性の過活動膀胱症状を治療するためのビベグロンの使用
US20210077495A1 (en) Use of vibegron to treat overactive bladder
CA2809966A1 (en) Treatment for cocaine addiction
CN118284412A (zh) 伴中度至重度焦虑和/或社交回避的自闭症谱系障碍受试者易怒症的治疗
US11166922B2 (en) Method for treating hyperhidrosis with dexmecamylamine
US20050009862A1 (en) Method for promoting uninterrupted sleep by administration of trospium chloride
US8901177B2 (en) Method of treating bladder disorders
HK40126413A (en) Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia
EA052961B1 (ru) Вибегрон для лечения симптомов гиперактивного мочевого пузыря
WO2024211216A1 (en) Cilnidipine and a p-glycoprotein inhibitor for treating pain
BR122024021845A2 (pt) Usos de vibegron para tratar sintomas de bexiga hiperativa e reduzir ou diminuir as micções
Verma et al. STUDY OF THE BIOEQUIVALENCE OF ANTI-BENIGN PROSTATIC HYPERPLASIA DRUG IN HEALTHY ADULT, MALE HUMAN SUBJECTS, UNDER FED CONDITION
Sherwood et al. Pharmacological Agents for the Treatment of Adult Attention Deficit Hyperactivity Disorder: A Review of the Literature

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601